NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Telix Pharmaceuticals Ltd. TLX
4 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 803.8M
Revenue, FY2025 · full 4-year series below
Revenue $M
Net income $M
FY2025 · Revenue 803.8 · Net income -7.1
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−1 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating 3.7% · Net -0.9%
ROE
Not available in our data for this period.
The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | 0.8 | 0.5 | 0.3 | · |
| Operating income $B | 0.0 | 0.1 | 0.0 | · |
| EBITDA $B | 0.1 | 0.1 | 0.0 | −0.1 |
| Income tax $B | 0.0 | 0.0 | −0.0 | · |
| Net income $B | −0.0 | 0.0 | 0.0 | · |
| Free cash flow $B | −0.0 | 0.0 | 0.0 | −0.1 |
| EPS, diluted $ | −0.02 | 0.10 | 0.01 | · |
| Dividend / sh $ | · | · | · | · |
| Payout % | · | · | · | · |
| ROE % | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 3 failures in 18 reconciliationsAUDITED
Reconciled in 2 of 19 fiscal years. 77 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente3 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsDecember 31
Data on record since2022